Processa Pharmaceuticals, Inc. Financing Cash Flow
Processa Pharmaceuticals, Inc. (PCSA) reported Financing Cash Flow of $559.95 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $315.17K, a 95.01% decline year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $244.78K, a 94.48% decline year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.98M, a 444.05% increase year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.86M, a 208.38% increase year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $16.58M, a 114.40% increase from fiscal 2024.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.73M, a 23.37% increase from fiscal 2023.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $6.27M.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$388.84K, a 103.97% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed | Net Cash Provided by (Used in) Financing Activities 27 month | Net Cash Provided by (Used in) Financing Activities 30 month | Net Cash Provided by (Used in) Financing Activities 33 month | Net Cash Provided by (Used in) Financing Activities 36 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $315.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $559.95K 10-Q · filed 2026-08-14 | $3.54M derived: sum of 3 quarters · filed 2026-08-14 | $6.40M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2026-03-31 | $244.78K 10-Q · filed 2026-05-07 | $3.22M derived: sum of 2 quarters · filed 2026-05-07 | $6.08M derived: sum of 3 quarters · filed 2026-05-07 | $12.39M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $5.84M derived: sum of 2 quarters · filed 2026-03-18 | $12.15M derived: sum of 3 quarters · filed 2026-08-14 | $16.58M 10-K · filed 2026-03-18 | ||||||
| 2025-09-30 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.17M derived: sum of 2 quarters · filed 2026-08-14 | $13.60M 10-Q · filed 2025-11-06 | $14.15M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-06-30 | $6.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.75M 10-Q · filed 2026-08-14 | $11.29M derived: sum of 3 quarters · filed 2026-08-14 | $12.22M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-03-31 | $4.44M 10-Q · filed 2026-05-07 | $4.98M derived: sum of 2 quarters · filed 2026-05-07 | $5.91M derived: sum of 3 quarters · filed 2026-05-07 | $5.91M derived: sum of 4 quarters · filed 2026-05-07 | ||||||
| 2024-12-31 | $547.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.47M derived: sum of 2 quarters · filed 2026-03-18 | $1.47M derived: sum of 3 quarters · filed 2026-03-18 | $7.73M 10-K · filed 2026-03-18 | ||||||
| 2024-09-30 | $926.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $922.78K derived: sum of 2 quarters · filed 2025-11-06 | $7.19M 10-Q · filed 2025-11-06 | $7.16M derived: sum of 4 quarters · filed 2025-11-06 | ||||||
| 2024-06-30 | -$3.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.26M 10-Q · filed 2025-08-07 | $6.23M derived: sum of 3 quarters · filed 2025-08-07 | $6.18M derived: sum of 4 quarters · filed 2025-08-07 | ||||||
| 2024-03-31 | $6.26M 10-Q · filed 2025-05-08 | $6.23M derived: sum of 2 quarters · filed 2025-05-08 | $6.18M derived: sum of 3 quarters · filed 2025-05-08 | $6.18M derived: sum of 4 quarters · filed 2025-05-08 | ||||||
| 2023-12-31 | -$30.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$83.35K derived: sum of 2 quarters · filed 2025-03-20 | -$83.35K derived: sum of 3 quarters · filed 2025-03-20 | $6.27M 10-K · filed 2025-03-20 | ||||||
| 2023-09-30 | -$52.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$52.75K derived: sum of 2 quarters · filed 2024-10-30 | $6.30M 10-Q · filed 2024-10-30 | $6.25M derived: sum of 4 quarters · filed 2024-10-30 | ||||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $6.35M 10-Q · filed 2024-08-13 | $6.30M derived: sum of 3 quarters · filed 2024-08-13 | $6.26M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $6.35M 10-Q · filed 2024-05-10 | $6.30M derived: sum of 2 quarters · filed 2024-05-10 | $6.26M derived: sum of 3 quarters · filed 2024-05-10 | $6.26M derived: sum of 4 quarters · filed 2024-05-10 | ||||||
| 2022-12-31 | -$53.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$88.84K derived: sum of 2 quarters · filed 2024-03-29 | -$88.84K derived: sum of 3 quarters · filed 2024-03-29 | -$388.84K 10-K · filed 2024-03-29 | ||||||
| 2022-09-30 | -$35.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$35.25K derived: sum of 2 quarters · filed 2023-11-13 | -$335.25K 10-Q · filed 2023-11-13 | -$203.88K derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$300.00K 10-Q · filed 2023-08-10 | -$168.64K derived: sum of 3 quarters · filed 2023-08-10 | -$353.82K derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | -$300.00K 10-Q · filed 2023-05-15 | -$168.64K derived: sum of 2 quarters · filed 2023-05-15 | -$353.82K derived: sum of 3 quarters · filed 2023-05-15 | -$376.90K derived: sum of 4 quarters · filed 2023-05-15 | ||||||
| 2021-12-31 | $131.36K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$53.82K derived: sum of 2 quarters · filed 2023-03-30 | -$76.90K derived: sum of 3 quarters · filed 2023-03-30 | $9.80M 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | -$185.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$208.26K derived: sum of 2 quarters · filed 2022-11-08 | $9.67M 10-Q · filed 2022-11-08 | $27.03M derived: sum of 4 quarters · filed 2022-11-08 | ||||||
| 2021-06-30 | -$23.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.85M 10-Q · filed 2022-08-11 | $27.22M derived: sum of 3 quarters · filed 2022-08-11 | $27.06M derived: sum of 4 quarters · filed 2022-08-11 | ||||||
| 2021-03-31 | $9.88M 10-Q · filed 2022-05-12 | $27.24M derived: sum of 2 quarters · filed 2022-05-12 | $27.09M derived: sum of 3 quarters · filed 2022-05-12 | $27.75M derived: sum of 4 quarters · filed 2022-05-12 | ||||||
| 2020-12-31 | $17.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $17.21M derived: sum of 2 quarters · filed 2022-03-30 | $17.87M derived: sum of 3 quarters · filed 2022-03-30 | $17.87M 10-K · filed 2022-03-30 | ||||||
| 2020-09-30 | -$156.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $504.54K derived: sum of 2 quarters · filed 2021-11-12 | $501.73K 10-Q · filed 2021-11-12 | $1.30M derived: sum of 4 quarters · filed 2021-11-12 | ||||||
| 2020-06-30 | $660.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $658.15K 10-Q · filed 2021-08-12 | $1.46M derived: sum of 3 quarters · filed 2021-08-12 | $1.96M derived: sum of 4 quarters · filed 2021-08-12 | ||||||
| 2020-03-31 | -$2.81K 10-Q · filed 2021-05-13 | $797.91K derived: sum of 2 quarters · filed 2021-05-13 | $1.30M derived: sum of 3 quarters · filed 2021-05-13 | $1.58M derived: sum of 4 quarters · filed 2021-05-13 | ||||||
| 2019-12-31 | $800.72K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.30M derived: sum of 2 quarters · filed 2021-03-25 | $1.59M derived: sum of 3 quarters · filed 2021-03-25 | $1.70M 10-K · filed 2021-03-25 | ||||||
| 2019-09-30 | $504.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $785.00K derived: sum of 2 quarters · filed 2020-11-12 | $900.00K 10-Q · filed 2020-11-12 | $680.71K derived: sum of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | $280.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $395.93K 10-Q · filed 2020-08-05 | $176.64K derived: sum of 3 quarters · filed 2020-08-05 | $285.66K derived: sum of 4 quarters · filed 2020-08-05 | ||||||
| 2019-03-31 | $115.00K 10-Q · filed 2020-05-15 | -$104.29K derived: sum of 2 quarters · filed 2020-05-15 | $4.74K derived: sum of 3 quarters · filed 2020-05-15 | |||||||
| 2018-12-31 | -$219.29K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | -$110.26K derived: sum of 2 quarters · filed 2020-03-06 | $2.62M 10-K · filed 2020-03-06 | |||||||
| 2018-09-30 | $109.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $2.84M 10-Q · filed 2019-11-14 | ||||||||
| 2018-06-30 | $2.73M 10-Q · filed 2019-08-14 | |||||||||
| 2017-12-31 | $2.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-04-08 | $2.35M derived: sum of 2 quarters · filed 2019-04-08 | $2.43M 10-K/A · filed 2019-04-08 | |||||||
| 2017-09-30 | -$150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$75.00K 10-Q · filed 2018-11-14 | $327.00K 10-Q · filed 2017-11-20 | |||||||
| 2017-06-30 | $75.00K 10-Q · filed 2017-10-04 | |||||||||
| 2016-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-16 | $4.25M derived: sum of 2 quarters · filed 2018-04-16 | $4.25M derived: sum of 3 quarters · filed 2018-04-16 | $4.27M 10-K · filed 2018-04-16 | $15.00K 10-K · filed 2017-09-25 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $0.00 derived: sum of 2 quarters · filed 2017-11-20 | $15.00K 10-Q · filed 2017-11-20 | $15.00K derived: sum of 4 quarters · filed 2017-11-20 | ||||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | $15.00K 10-Q · filed 2017-10-04 | $15.00K derived: sum of 3 quarters · filed 2017-10-04 | $62.13K derived: sum of 4 quarters · filed 2017-10-04 | ||||||
| 2016-03-31 | $15.00K 10-Q · filed 2017-10-04 | $15.00K derived: sum of 2 quarters · filed 2017-10-04 | $62.13K derived: sum of 3 quarters · filed 2017-10-04 | $312.06K derived: sum of 4 quarters · filed 2017-10-04 | ||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $47.13K derived: sum of 2 quarters · filed 2017-09-25 | $297.06K derived: sum of 3 quarters · filed 2017-09-25 | $821.10K 10-K · filed 2017-09-25 | ||||||
| 2015-09-30 | $47.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $297.06K derived: sum of 2 quarters · filed 2017-09-08 | $821.10K 10-Q · filed 2017-09-08 | $1.27M derived: sum of 4 quarters · filed 2017-09-08 | ||||||
| 2015-06-30 | $249.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | $773.97K 10-Q · filed 2017-08-30 | $1.22M derived: sum of 3 quarters · filed 2017-08-30 | $1.79M derived: sum of 4 quarters · filed 2017-08-30 | ||||||
| 2015-03-31 | $524.04K 10-Q · filed 2017-08-07 | $971.50K derived: sum of 2 quarters · filed 2017-08-07 | $1.54M derived: sum of 3 quarters · filed 2017-08-07 | $2.21M derived: sum of 4 quarters · filed 2017-08-07 | ||||||
| 2014-12-31 | $447.46K derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | $1.01M derived: sum of 2 quarters · filed 2017-06-19 | $1.68M derived: sum of 3 quarters · filed 2017-06-19 | $2.57M 10-K · filed 2017-06-19 | ||||||
| 2014-09-30 | $566.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | $1.23M derived: sum of 2 quarters · filed 2015-12-01 | $2.13M 10-Q · filed 2015-12-01 | $1.78M derived: sum of 4 quarters · filed 2015-12-01 | ||||||
| 2014-06-30 | $667.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | $1.56M 10-Q · filed 2015-08-19 | $1.21M derived: sum of 3 quarters · filed 2015-08-19 | $2.32M derived: sum of 4 quarters · filed 2015-08-19 | ||||||
| 2014-03-31 | $893.54K 10-Q · filed 2015-05-15 | $547.00K derived: sum of 2 quarters · filed 2015-05-15 | $1.65M derived: sum of 3 quarters · filed 2015-05-15 | $2.63M derived: sum of 4 quarters · filed 2015-05-15 | $9.08M 10-Q · filed 2014-05-14 | |||||
| 2013-12-31 | -$346.53K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $755.26K derived: sum of 2 quarters · filed 2015-04-14 | $1.74M derived: sum of 3 quarters · filed 2015-04-14 | $1.73M 10-K · filed 2015-04-14 | $8.19M 10-K · filed 2014-03-27 | |||||
| 2013-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $2.09M derived: sum of 2 quarters · filed 2014-11-13 | $2.08M 10-Q · filed 2014-11-13 | $2.16M 10-Q · filed 2013-11-08 | $2.37M derived: sum of 4 quarters · filed 2014-11-13 | $8.62M 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | $983.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-19 | $976.57K 10-Q · filed 2014-08-19 | $1.27M derived: sum of 3 quarters · filed 2014-08-19 | $7.43M 10-Q/A · filed 2013-09-06 | ||||||
| 2013-03-31 | -$6.74K 10-Q · filed 2014-05-14 | $284.63K derived: sum of 2 quarters · filed 2014-05-14 | ||||||||
| 2012-12-31 | $291.37K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $453.38K 10-K · filed 2014-03-27 | ||||||||
| 2012-09-30 | $162.01K 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |